Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07519772 · ClinicalTrials.gov registry record · Phase 1
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 200
- Enrollment target
NCT07519772 is a Phase 1 study that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 200 participants.
The verdict
NCT07519772, a Phase 1 study, is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 200 participants
- Enrollment target
Study Summary
Researchers are looking for new ways to treat 2 types of non-Hodgkin lymphoma (NHL) called follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). FL is a slow-growing type of NHL. DLBCL is a fast-growing type of NHL. NHL is a cancer in the lymphatic system that causes swollen lymph nodes. The lymphatic system is part of the immune system. In this study, researchers want to learn if MK-1045 can treat FL and DLBCL. MK-1045 is a study treatment that is an immunotherapy, which helps the immune system fight cancer. The goals of this study are to learn how safe MK-1045 is and if people tolerate it. Researchers also want to see if FL and DLBCL respond (the cancer gets smaller or goes away) to treatment.
Interventions
- BIOLOGICAL MK-1045
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2026-05-03 |
| Est. Completion | 2031-04-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07519772
The ClinicalTrials.gov registry entry for NCT07519772 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MK-1045 is the first listed.
NCT07519772 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07519772 about?
NCT07519772 is a clinical study titled "A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)". Researchers are looking for new ways to treat 2 types of non-Hodgkin lymphoma (NHL) called follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). FL is a slow-growing type of NHL. DLBCL is a fast-growing type of NHL. NHL is a cancer in the lymphatic system that causes swollen lymph node...
What is the current status of trial NCT07519772?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 200 participants. The study started on 2026-05-03. Estimated completion is 2031-04-01.
What interventions are being tested in trial NCT07519772?
The interventions under investigation include: MK-1045 (BIOLOGICAL).
Who is sponsoring clinical trial NCT07519772?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.